Martina Zandl_Lang

Dr. Martina Zandl_Lang

Medical University of Graz
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Verified
Journal Article
Closed access
MZMartina Zandl_Lang
Martina Zandl_Lang
EFElham Fanaee-Danesh
Elham Fanaee-Danesh
YSYidan Sun
Yidan Sun
NANicole M. Albrecher
Nicole M. Albrecher
CGChaitanya Chakravarthi Gali
Chaitanya Chakravarthi Gali
UPUte Panzenboeck
Ute Panzenboeck

1 June 2017 in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Verified
Journal Article
Closed access
AKAlexandra Carmen Kober
Alexandra Carmen Kober
AMAnil Paul Chirackal Manavalan
Anil Paul Chirackal Manavalan
CTCarmen Tam-Amersdorfer
Carmen Tam-Amersdorfer
AHAndreas Holmér
Andreas Holmér
ASAhmed Saeed
Ahmed Saeed
UPUte Panzenboeck
Ute Panzenboeck

1 September 2019 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
EFElham Fanaee-Danesh
Elham Fanaee-Danesh
CGChaitanya Chakravarthi Gali
Chaitanya Chakravarthi Gali
JTJelena Tadic
Jelena Tadic
MZMartina Zandl_Lang
Martina Zandl_Lang
AKAlexandra Carmen Kober
Alexandra Carmen Kober
UPUte Panzenboeck
Ute Panzenboeck

1 September 2018 in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Verified
Journal Article
Closed access
YSYidan Sun
Yidan Sun
SKSusanne Kopp
Susanne Kopp
JSJasmin Strutz
Jasmin Strutz
CGChaitanya Chakravarthi Gali
Chaitanya Chakravarthi Gali
MZMartina Zandl_Lang
Martina Zandl_Lang
UPUte Panzenboeck
Ute Panzenboeck

25 August 2020 in Metabolites
Verified
Journal Article
Open access
PDF file
TZThomas Züllig
Thomas Züllig
MZMartina Zandl_Lang
Martina Zandl_Lang
MTMartin Trötzmüller
Martin Trötzmüller
Jürgen HartlerJürgen Hartler
Jürgen Hartler
BPBarbara Plecko
Barbara Plecko
Harald KöfelerHarald Köfeler
Harald Köfeler
In the highly dynamic field of metabolomics, we have developed a method for the analysis of hydrophilic metabolites in various biological samples. Therefore, we used hydrophilic interaction chromatography (HILIC) for separation, combined with a high-resolution mass spectrometer (MS) with the aim of separating and analyzing a wide range of compounds. We used 41 reference standards with different chemical properties to develop an optimal chromatographic separation. MS analysis was performed with a set of pooled biological samples human cerebrospinal fluid (CSF), and human plasma. The raw data was processed in a first step with Compound Discoverer 3.1 (CD), a software tool for untargeted metabolomics with the aim to create a list of unknown compounds. In a second step, we combined the results obtained with our internally analyzed reference standard list to process the data along with the Lipid Data Analyzer 2.6 (LDA), a software tool for a targeted approach. In order to demonstrate the advantages of this combined target-list based and untargeted approach, we not only compared the relative standard deviation (%RSD) of the technical replicas of pooled plasma samples (n = 5) and pooled CSF samples (n = 3) with the results from CD, but also with XCMS Online, a well-known software tool for untargeted metabolomics studies. As a result of this study we could demonstrate with our HILIC-MS method that all standards could be either separated by chromatography, including isobaric leucine and isoleucine or with MS by different mass. We also showed that this combined approach benefits from improved precision compared to well-known metabolomics software tools such as CD and XCMS online. Within the pooled plasma samples processed by LDA 68% of the detected compounds had a %RSD of less than 25%, compared to CD and XCMS online (57% and 55%). The improvements of precision in the pooled CSF samples were even more pronounced, 83% had a %RSD of less than 25% compared to CD and XCMS online (28% and 8% compounds detected). Particularly for low concentration samples, this method showed a more precise peak area integration with its 3D algorithm and with the benefits of the LDAs graphical user interface for fast and easy manual curation of peak integration. The here-described method has the advantage that manual curation for larger batch measurements remains minimal due to the target list containing the information obtained by an untargeted approach.

25 March 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
MZMartina Zandl_Lang
Martina Zandl_Lang
TZThomas Züllig
Thomas Züllig
MTMartin Trötzmüller
Martin Trötzmüller
YNYvonne Naegelin
Yvonne Naegelin
LALucia Abela
Lucia Abela
BPBarbara Plecko
Barbara Plecko
Rett syndrome (RTT) is defined as a rare disease caused by mutations of the methyl-CpG binding protein 2 (MECP2). It is one of the most common causes of genetic mental retardation in girls, characterized by normal early psychomotor development, followed by severe neurologic regression. Hitherto, RTT lacks a specific biomarker, but altered lipid homeostasis has been found in RTT model mice as well as in RTT patients. We performed LC-MS/MS lipidomics analysis to investigate the cerebrospinal fluid (CSF) and plasma composition of patients with RTT for biochemical variations compared to healthy controls. In all seven RTT patients, we found decreased CSF cholesterol levels compared to age-matched controls (n = 13), whereas plasma cholesterol levels were within the normal range in all 13 RTT patients compared to 18 controls. Levels of phospholipid (PL) and sphingomyelin (SM) species were decreased in CSF of RTT patients, whereas the lipidomics profile of plasma samples was unaltered in RTT patients compared to healthy controls. This study shows that the CSF lipidomics profile is altered in RTT, which is the basis for future (functional) studies to validate selected lipid species as CSF biomarkers for RTT.